Share your videos with the world

Let’s get ready to rumble! Auction specialists Billy “The Dealer” Leroy,” Mark “The Hustler” Meyer, and Laurence & Sally Martin – “The Wild Cards,” are back for a new season of Travel Channel’s original series “Baggage Battles” premiering with back-to-back episodes on Tuesday, October 15 at 9:00 p.m. and 9:30 p.m. ET/PT. In season three, the popular weekly half-hour series continues to give viewers a glimpse into the very profitable business of bidding, buying and reselling of unclaimed items from auctions around the world including airport, freight and shipping, estate, police and seizure, and specialty auctions. The stakes are higher for the expert teams of savvy buyers who still don’t know if it’s junk or jackpot until they win the bid. To view Multimedia News Release, go to http://www.multivu.com/mnr/63403-travel-channel-baggage-battles-season-3

GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience. To view the multimedia release go to: https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/